Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Published:2024 Issue: Volume:6 Page:100179
ISSN:2590-2571
Container-title:Current Research in Pharmacology and Drug Discovery
language:en
Short-container-title:Current Research in Pharmacology and Drug Discovery

Author:

Badreldin Hisham A.,Alsuhebany Nada,Alzahrani Mohammed,Alshehri Abdulmajeed M.,Aldoughaim Maha,Alqifari Saleh,Yassin Omar,Alfehaid Lama^ORCID,Alqahtani Tariq

Publisher

Elsevier BV

Reference17 articles.

1. Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and Arterial thrombotic disorders;Campello;J. Clin. Med.,2022

2. Direct oral anticoagulant Use: a Practical Guide to Common clinical challenges;Chen;J. Am. Heart Assoc.,2020

3. The evolution of anticoagulant therapy;Franchini;Blood Transfus,2016

4. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans;Koch;Blood,2019

5. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism;Li;Front Cardiovasc Med,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP